Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-cash Items (2017 - 2025)

Historic Non-cash Items for Dianthus Therapeutics (DNTH) over the last 6 years, with Q3 2025 value amounting to $126.2 million.

  • Dianthus Therapeutics' Non-cash Items rose 15746.34% to $126.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $126.2 million, marking a year-over-year increase of 15746.34%. This contributed to the annual value of $24.9 million for FY2024, which is 372241.68% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Non-cash Items of $126.2 million as of Q3 2025, which was up 15746.34% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Non-cash Items ranged from a high of $126.2 million in Q3 2025 and a low of $1.0 million during Q2 2024
  • Over the past 4 years, Dianthus Therapeutics' median Non-cash Items value was $5.5 million (recorded in 2023), while the average stood at $26.9 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Non-cash Items skyrocketed by 68173.53% in 2024, and later plummeted by 9639.55% in 2025.
  • Dianthus Therapeutics' Non-cash Items (Quarter) stood at $1.7 million in 2022, then surged by 87.12% to $3.2 million in 2023, then soared by 681.74% to $24.9 million in 2024, then soared by 407.6% to $126.2 million in 2025.
  • Its Non-cash Items stands at $126.2 million for Q3 2025, versus $2.2 million for Q2 2025 and $1.8 million for Q1 2025.